Brief: Resmed Q2 Adjusted EPS USD 2.81 Vs. IBES Estimate USD 2.72
29/01/2026 21:05
Jan 29 (Reuters) - Resmed Q2 revenue USD 1,400 million vs. IBES estimate USD 1,396 million. Q2 adjusted gross margin 62.3% Q2 EPS USD 2.68
Recent news on ResMed
See all newsCiti lifts ResMed's ASX-listed stock's target price after FX, valuation updates
S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT
S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT
Brief: Resmed - Enters Accelerated Share Repurchase Agreement To Repurchase $450 Million Of Common Stock - SEC Filing
S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT